hemotune AG is a spin-off company originating out of the Functional Materials Lab at ETH Zurich. Hemotune was founded in 2017 and is currently incubated at Wyss Zurich. The company concluded a Series A VC-backed investment round in August 2020 and won prestigious grants in Switzerland and the EU.
At hemotune, a highly motivated and interdisciplinary team composed of scientists, engineers, as well as regulatory and clinical specialists jointly works on the development and commercialization of HemoSystemTM. HemoSystemTM is a breakthrough blood purification platform based on nanoengineered magnetic beads that enables revolutionary intervention strategies, mainly designed for sepsis patients. hemotune’s innovative approach focuses on the immunological aspect of this devastating disease, thereby tackling multiple disease pathways in parallel. First-in-man trials are planned in 2022.